NCT02824055View on ClinicalTrials.gov

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 27, 2016

Primary Completion Date

April 24, 2017

Study Completion Date

April 24, 2017

Conditions
Schizophrenia
Interventions
DRUG

Placebo

Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.

DRUG

RO5545965

Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.

Trial Locations (3)

63141

St Louis Clinical Trials, St Louis

91206

Parexel California Clinical Trials Medical Group, Glendale

92845

CNS Network, Garden Grove

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02824055 - A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics | Biotech Hunter | Biotech Hunter